Endoscopic Retrograde Cholangiopancreatography

ConditionGastro-Intestinal Disorder

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age15+

SponsorMethodist Health System

About this trial

The risk of post-endoscopic retrograde cholangiopancreatography(ERCP) pancreatitis(PEP) is influenced by patient and procedure-related factors. Strategies to decrease PEP(Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis) are of great importance.

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

Patients undergoing ERCPs at Methodist Dallas Medical Center

Treatment groups

100 Participants

are divided into 1 treatment group

Sponsors and collaborators

Methodist Health System

Lead sponsor

Source ClinicalTrials.gov